Acurx Pharmaceuticals (ACXP) vs Curanex Pharmaceuticals (CURX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Curanex Pharmaceuticals is the larger company by market cap ($8.2 million vs $7.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | CURX |
|---|---|---|
| Share price | $1.26 | $5.24 |
| Market cap | $7.00M | $8.22M |
| 1-day change | +0.80% | +10.08% |
| EPS (TTM) | $-2.67 | $-7.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $16.94 |
| 52-week low | $1.23 | $3.58 |
| Distance from 52-week high | -84.21% | -69.07% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1249.21% | — |
| Average volume | 125.08K | 19.85K |
| Shares outstanding | 5.56M | 1.57M |
| Employees | 4 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Curanex Pharmaceuticals
CURX stock →Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
ACXP vs CURX FAQ
Which is bigger, Acurx Pharmaceuticals or Curanex Pharmaceuticals?
Curanex Pharmaceuticals (CURX) is larger, with a market capitalization of $8.22M compared with $7.00M for Acurx Pharmaceuticals (ACXP).
Are Acurx Pharmaceuticals and Curanex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.